Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

T cell engagers emerge as a compelling therapeutic modality.

The Journal of experimental medicine·2025
Same author

Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.

Leukemia·2016
Same author

Differential localization of A-Raf regulates MST2-mediated apoptosis during epithelial differentiation.

Cell death and differentiation·2016
Same author

EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205.

British journal of cancer·2014
Same author

Context-dependent adaption of EpCAM expression in early systemic esophageal cancer.

Oncogene·2013
Same author

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.

Leukemia·2012

Related Experiment Video

Updated: Jul 17, 2026

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells
12:14

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells

Published on: June 2, 2022

EpCAM (CD326) finding its role in cancer.

P A Baeuerle1, O Gires

  • 1Micromet, Inc., 2110 Rutherford Road, Carlsbad, CA, 92008, USA. Patrick.baeuerle@micromet-inc.com

British Journal of Cancer
|January 11, 2007
PubMed
Summary

Epithelial cell adhesion molecule (EpCAM) is a key cancer target. Recent research explores EpCAM

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Background:

  • Epithelial cell adhesion molecule (EpCAM/CD326), identified early as a tumor-associated antigen, has been historically under-investigated for cancer therapy.
  • The specific role of EpCAM in carcinogenesis remained largely unexplored until recent advancements.
  • The First International Symposium on EpCAM Biology and Clinical Application marked a turning point in EpCAM research.

Purpose of the Study:

  • To consolidate current knowledge and future directions regarding EpCAM in cancer.
  • To discuss EpCAM's expression, prognostic value, and oncogenic signaling roles.
  • To review EpCAM-directed immunotherapeutic strategies and potential therapeutic windows.

Main Methods:

  • Discussion and synthesis of findings presented at the First International Symposium on EpCAM Biology and Clinical Application.

More Related Videos

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Discovery of Metastatic Regulators using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model
07:03

Discovery of Metastatic Regulators using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model

Published on: February 3, 2021

Related Experiment Videos

Last Updated: Jul 17, 2026

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells
12:14

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells

Published on: June 2, 2022

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Discovery of Metastatic Regulators using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model
07:03

Discovery of Metastatic Regulators using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model

Published on: February 3, 2021

  • Review of existing literature on EpCAM expression, function, and therapeutic targeting.
  • Analysis of EpCAM's interaction with other proteins for therapeutic insights.

    • Main Results:

    • EpCAM expression frequency and levels across various cancers and their prognostic significance were key discussion points.
    • EpCAM's function as an oncogenic signaling molecule in cancer cells was highlighted.
    • Progress in EpCAM-directed immunotherapies and potential strategies to inhibit its growth-promoting signaling were presented.

    Conclusions:

    • EpCAM is gaining recognition as a significant target for cancer therapy and research.
    • Understanding EpCAM's multifaceted roles in carcinogenesis is crucial for developing effective treatments.
    • Future research should focus on unified nomenclature and interdisciplinary collaboration for EpCAM-targeted therapies.